Extractables & Leachables (E&L) Capabilities 

CA Analytical Testing Services provides comprehensive Extractables & Leachables (E&L) testing for pharmaceuticals, medical devices, combination products, bioprocessing systems, and packaging materials. Our laboratory delivers regulatory‑aligned, science‑based testing with complete documentation for FDA, USP <1663>/<1664>, USP <665>/<1665> , and PQRI expectations. 

Core E&L Capabilities 

– Complete Extractables studies (controlled extraction) 
– Comprehensive Leachables studies under real-time and accelerated conditions 
– Material compatibility and risk‑based assessments 
– Orthogonal analytical screening to maximize coverage 
– Specialized workflows for polymeric materials, elastomers, tubing, closures, bioreactors, and prefilled syringes 

Analytical Techniques 

• LC‑MS/MS (Small molecules, semi-volatiles, non-volatiles) 
• GC‑MS and GC‑MS/MS (Volatiles and semi-volatiles) 
• ICP‑MS (Metals, catalyst residues, elemental impurities) 
• Headspace GC‑MS (Residual solvents) 
• FTIR (Polymer identification) 
• UV‑Vis, CAD, pH (Supporting tests) 
 

Extractables Study Workflow

  1. Controlled extraction using solvents (polar/non‑polar), elevated temperature, and time. 
  2. Orthogonal screening: GC‑MS, LC‑MS, ICP‑MS. 
  3. Tentative identification using spectral libraries and HRAM tools. 
  4. Semi‑quantification relative to surrogate standards. 
  5. Full reporting and toxicological alignment. 

Leachables Study Workflow 

  1. Real‑time and accelerated storage conditions 
  2. Method development and validation for target analytes 
  3. Routine quantification at multiple timepoints 
  4. Toxicological evaluation support 

Regulatory Alignment 

  • Our E&L programs are aligned with: 
  • USP <1663> Extractables 
  • USP <1664> Leachables 
  • USP <665>/<1665> Plastic components and systems 
  • PQRI OINDP, Parenteral, and PODP recommendations 
  • ISO 10993, FDA, ICH Q3E, and industry best practices 

Industries Supported 

– Pharmaceutical manufacturers 
– Medical device companies 
– Biologics and cell/gene therapy groups 
– Packaging and component manufacturers 
– CDMOs and CMOs 

Turnaround Times 

  • Typical controlled extractables study: 3–4 weeks 
  • Leachables programs follow customer study design 

Deliverables 

  • Full E&L study protocol 
  • Detailed analytical results and chromatograms 
  • Tentative IDs with library match scores 
  • Semi‑quantitative and quantitative data 
  • Toxicological risk assessment support

Extractables are chemical compounds that can be pulled out of a material—such as plastics, elastomers, tubing, or container–closure systems—when exposed to aggressive solvents, elevated temperatures, or exaggerated laboratory conditions. Extractables studies identify the full chemical profile of what could migrate from a material under worst-case scenarios.

Leachables are chemical compounds that actually migrate from packaging, processing equipment, or device components into the real drug product or clinical solution under normal storage, use, and shelf-life conditions. Leachables studies focus on what does migrate, using targeted, validated methods to ensure patient safety and regulatory compliance.

Ready to test with CA?

BOOK AN APPOINTMENT
GET A QUOTE